Statistical analysis of base-line and 12 months follow-up distribution concerning individuals with or without manifested T2D revealed no significant differences for the cohort of LCD participants (Figure 3D), whereas a significant improvement of T2D (defined as HbA1c below 6.5% at 12 months follow-up without insulin, GLP1 analogs, and oral anti-diabetic medication) was observed among bariatric surgery patients after RYGB (Figure 3E). The gene discussed is INS; the disease is type 2 diabetes mellitus.